256 related articles for article (PubMed ID: 33440348)
1. Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.
Wen Z; Feng Y; Hu Y; Lian L; Huang H; Guo L; Chen S; Yang Q; Zhang M; Wan L; Xu K; Degejirifu ; Yan X
Aging (Albany NY); 2021 Jan; 13(2):1872-1882. PubMed ID: 33440348
[TBL] [Abstract][Full Text] [Related]
2. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2.
Huang W; Xing Y; Zhu L; Zhuo J; Cai M
Exp Cell Res; 2021 Sep; 406(1):112633. PubMed ID: 34089726
[TBL] [Abstract][Full Text] [Related]
5. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Yao Y; Su Z; Liang Y; Zhang N
Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma.
Yao Y; Wang T; Liu Y; Zhang N
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1374-1383. PubMed ID: 30977418
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib-Loaded Long-Circulating Nanoliposomes for Liver Cancer Therapy.
Ye H; Zhou L; Jin H; Chen Y; Cheng D; Jiang Y
Biomed Res Int; 2020; 2020():1351046. PubMed ID: 32461962
[TBL] [Abstract][Full Text] [Related]
8. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
[TBL] [Abstract][Full Text] [Related]
9. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
Zan Y; Dai Z; Liang L; Deng Y; Dong L
Drug Deliv; 2019 Dec; 26(1):1080-1091. PubMed ID: 31735093
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
12. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
Nour MA; Kheradmand F; Rasmi Y; Baradaran B
Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
[TBL] [Abstract][Full Text] [Related]
13. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model.
Podesta JE; Al-Jamal KT; Herrero MA; Tian B; Ali-Boucetta H; Hegde V; Bianco A; Prato M; Kostarelos K
Small; 2009 May; 5(10):1176-85. PubMed ID: 19306454
[TBL] [Abstract][Full Text] [Related]
15. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Younis MA; Khalil IA; Abd Elwakil MM; Harashima H
Mol Pharm; 2019 Sep; 16(9):4031-4044. PubMed ID: 31403802
[TBL] [Abstract][Full Text] [Related]
16. Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.
Cho HJ; Chong S; Chung SJ; Shim CK; Kim DD
Pharm Res; 2012 Apr; 29(4):1007-19. PubMed ID: 22169985
[TBL] [Abstract][Full Text] [Related]
17. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo.
Younis MA; Khalil IA; Elewa YHA; Kon Y; Harashima H
J Control Release; 2021 Mar; 331():335-349. PubMed ID: 33484779
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment.
Chen B; Pan Y; Xu X; Wu F; Zheng X; Chen SY; Zhao YT; Huang Z; Cheng SH; Liu JX; Wang WH; Li YX
Biomed Pharmacother; 2020 Aug; 128():110284. PubMed ID: 32480224
[TBL] [Abstract][Full Text] [Related]
19. Design of Cationic Multiwalled Carbon Nanotubes as Efficient siRNA Vectors for Lung Cancer Xenograft Eradication.
Guo C; Al-Jamal WT; Toma FM; Bianco A; Prato M; Al-Jamal KT; Kostarelos K
Bioconjug Chem; 2015 Jul; 26(7):1370-9. PubMed ID: 26036843
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
